Navigation Links
Sunesis to Present at Upcoming Conferences
Date:11/3/2008

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at the following upcoming conferences:

Rodman & Renshaw 10th Annual Healthcare Conference

The New York Palace Hotel, New York

Wednesday, November 12, 2008

2:00 p.m. EST

Lazard Capital Markets 5th Annual Healthcare Conference

The St. Regis, New York

Tuesday, November 18, 2008

5:10 p.m. EST

BIO-Europe 2008

m:con Congress Center Rosengarten

Mannheim, Germany

Tuesday, November 18, 2008

9:15 a.m. CET / 3:15 a.m. EST

Interested parties may access a webcast of the Rodman & Renshaw and Lazard Capital presentations by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and th
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
2. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
3. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
6. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
7. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
8. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... the University of Illinois at Urbana-Champaign have demonstrated ... (pBNAs) can be used like traditional photographic film ... smaller than the wavelength of light (for example, ... A standard optical microscope acts as a "nanocamera" ... "Unlike conventional photographic film, the effect (writing and ...
(Date:7/18/2014)... 18, 2014 Emerging Nuclear Power Countries ... 2030 , Summary , The latest report from GlobalData, ... and Development Analysis to 2030 covers the emerging nuclear ... provides comprehensive information on key market players and their ... in various countries across the world has also been ...
(Date:7/17/2014)... WASHINGTON , July 17, 2014  Vanda Pharmaceuticals ... company focused on the development and commercialization of products ... announced it will release results for the second quarter ... market opens. The Company will host ... August 7, 2014, during which Vanda management will discuss ...
(Date:7/17/2014)... major road blocks to the design and development of ... Researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) ... meaning a theoretical model free of adjustable or ... carriers" in semiconductors. Hot carriers are electrical charge carriers ... than charge carriers at thermal equilibrium. , "Hot carrier ...
Breaking Biology Technology:'Nanocamera' takes pictures at distances smaller than light's own wavelength 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014 2First ab initio method for characterizing hot carriers 2First ab initio method for characterizing hot carriers 3
... Aureus Pharma, a leading provider of,knowledge management ... release today of the new software solution ... evaluate target, cell and,drug profiles using bio-assays ... Pharma,s AurSCOPE Target Knowledge databases. AurPROFILER has ...
... Inc., the,operating company of WuXi PharmaTech (NYSE: ... of Garry Takle, Ph.D. as Vice President of ... Testing Services for its,Philadelphia facility., (Logo: ... with the company for nine years in roles ...
... HILL, N.C., Aug. 15 The U.S. ... into multiple market,segments. In this challenging marketplace, ... complex organizational and,decision-making structures to effectively represent ... being influenced by medical professionals,focused on efficacy ...
Cached Biology Technology:Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution 2WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility 2U.S. Hospital Sales Opportunities Maximized Through Functional Optimization 2
(Date:7/21/2014)... developed a pioneering new way using samples of ... of drugs on the heart without using human or ... Dr Helen Maddock an expert in cardiovascular physiology ... and Exercise Sciences and could lead to the ... the quality of their treatments improved. , Adverse effects ...
(Date:7/21/2014)... Boston, MA Scientists at Brigham and Women,s Hospital ... generate fully functional human platelets in vitro. The work ... blood transfusion needs worldwide. , The study is published ... "The ability to generate an alternative source of functional ... paradigm shift in how we collect platelets that may ...
(Date:7/21/2014)... July 21, 2014 Research and Markets ( ... "Next Generation Biometric Market by Technology, Function, ... 2014 - 2020" report to their offering. ... is the verification of humans by their characteristics ... vein, and DNA. DNA and vein recognition are ...
Breaking Biology News(10 mins):New technique uses 'simulated' human heart to screen drugs 2Scientists successfully generate human platelets using next-generation bioreactor 2Global Next Generation Biometric Market by Technology, Function, Application & by Geography - Forecasts & Analysis to 2020 2Global Next Generation Biometric Market by Technology, Function, Application & by Geography - Forecasts & Analysis to 2020 3
... reef, the Scken reef in the Koster Fjord, is ... the University of Gothenburg have started a restoration project ... being removed and placed on the Scken reef. ... In Sweden, only one reef-building coral species exists, a ...
... prone to extinction than others? A new study of marine ... million years of fossil data for marine invertebrates reveals that ... hit even when populations are large, the authors report. ... surface. But because monitoring data are harder to collect at ...
... -- Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian ... Food and Drug Administration (FDA) has granted Meridian,s ... (pre-IND) meeting to discuss its plan to commence ... various cancer indications. The meeting is scheduled for ...
Cached Biology News:Sweden's only coral reef at risk of dying 2Sweden's only coral reef at risk of dying 3Fossil study helps pinpoint extinction risks for ocean animals 2FDA Grants Meridian Laboratories Pre-Ind Meeting for Captisol-Enabled Docetaxel in the Treatment of Cancer 2
... omental preadipocytes are isolated ... healthy donors. There is ... cells. Please inquire for ... also available. Academic discounts ...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: